| US 7,544,657 B2 | ||
| Stabilized Exendin-4 compounds | ||
| Kirsten Ebbehøj, Nærum (Denmark); Trine Jepsen, Copenhagen (Denmark); Carsten Boye Knudsen, Greve (Denmark); Bjarne Due Larsen, Roskilde (Denmark); and David Knott, Hertford (Denmark) | ||
| Assigned to Zealand Pharma A/S, Glostrup (Denmark) | ||
| Appl. No. 10/529,858 PCT Filed Oct. 02, 2003, PCT No. PCT/DK03/00651 § 371(c)(1), (2), (4) Date Apr. 26, 2006, PCT Pub. No. WO2004/035623, PCT Pub. Date Apr. 29, 2004. |
||
| Claims priority of provisional application 60/415626, filed on Oct. 02, 2002. | ||
| Prior Publication US 2006/0194719 A1, Aug. 31, 2006 | ||
| Int. Cl. A61K 38/00 (2006.01) | ||
| U.S. Cl. 514—12 [514/2; 530/300; 530/308; 530/324] | 32 Claims |
| 1. A composition comprising an exendin-4 (1-39) analog comprising a sequence selected from the group consisting of:
[Asp28]Exendin-4 (1-39) (SEQ ID NO:83),
des Pro36[Asp28]Exendin-4 (1-39) (SEQ ID NO:15),
des Pro36, Pro37[Asp28]Exendin-4 (1-39) (SEQ ID NO:108), and
des Pro36, Pro37, Pro38[Asp28]Exendin-4 (1-39) (SEQ ID NO:28).
|